Group 1 - Aisheren (920050) experienced a significant increase of 175.59% on its first trading day, with a turnover rate of 78.23% and a transaction volume of 689 million yuan [2] - The stock's first-day margin trading saw a buy amount of 7.65 million yuan, accounting for 1.11% of the total trading volume, with a latest margin balance of 7.24 million yuan, representing 0.91% of the circulating market value [2] - The company focuses on the healthcare sector, primarily engaged in the research, production, and sales of disposable medical consumables used in professional rehabilitation care and medical protection, providing products for internationally renowned medical device brands through ODM/OEM methods [2] Group 2 - Recent IPOs have shown varying first-day performance, with Kema Materials (920086) rising by 371.27%, and Zhixin Stock (603352) increasing by 213.44% on their respective debut days [3] - The first-day margin balances for other recent IPOs include 7.49 million yuan for Kema Materials, which is 0.72% of its circulating market value, and 82.41 million yuan for Zhixin Stock, accounting for 2.71% [3] - The data indicates a trend of high volatility and investor interest in newly listed stocks, as evidenced by the substantial price increases and high turnover rates [3]

Core Viewpoint - The article discusses the recent surge in IPO activities on the Beijing Stock Exchange (北交所), highlighting the rapid pace of new stock listings and the strong market performance of newly listed companies, indicating a positive trend for investors and the market overall [3][4][6]. Group 1: IPO Activities - Three listing committee meetings and two new stock listings occurred within a week, with Aisheren (爱舍伦) debuting on January 21, 2026, and experiencing a significant first-day increase of 175.59%, closing at 44.04 yuan per share [3][4]. - Aisheren's IPO details include an issuance price of 15.98 yuan per share, a price-to-earnings ratio of 14.99, and total funds raised amounting to 270 million yuan [4]. - The upcoming listing of Guoliang New Materials (国亮新材) is set for January 22, 2026, contributing to a total of three new stocks listed in January [5]. Group 2: Market Performance - In 2025, the Beijing Stock Exchange had 26 new stocks listed, averaging about two per month, with some months seeing up to five listings [6]. - The average first-day increase for new stocks in 2025 was approximately 368%, with notable performers like Dapeng Industrial (大鹏工业) achieving a 1211.11% increase [6][8]. - The strong performance of new stocks has led to a significant market expectation for continued high returns, with no stocks experiencing a first-day drop in 2025 [6][8]. Group 3: Listing Review Acceleration - The listing review process on the Beijing Stock Exchange has accelerated, with six committee meetings held in January 2026 alone, indicating a trend of increased efficiency in the IPO process [7][8]. - Analysts note that the review process for specialized and innovative companies has become notably quicker, with some companies moving from application to approval in just a few months [8]. - The focus of the listing reviews appears to be on high-tech and advanced manufacturing sectors, reflecting a strategic support for these industries [8]. Group 4: Subscription and Frozen Capital - The subscription for new stocks has seen a significant increase, with frozen capital exceeding 800 billion yuan for several recent IPOs, indicating strong investor interest [9][12]. - Aisheren attracted 695,800 participants in its subscription, with a total frozen capital of 8789.21 million yuan [14]. - The upcoming IPOs of Nongda Technology (农大科技) and Meidel (美德乐) are expected to further increase the frozen capital, reflecting ongoing investor enthusiasm for new listings [16].

Group 1 - Aishalon is a company focused on the research, development, production, and sales of disposable medical consumables in the rehabilitation care and medical protection sectors [2] - The company emphasizes innovation and development, catering to the professional needs of healthcare workers and patients, and aims for technological innovation and industrial upgrades [2] - Aishalon has expanded its product line to include disinfection, household protection, and emergency protection products, while also providing ODM/OEM services for internationally recognized medical device brands [2] Group 2 - Aishalon operates multiple self-owned factories located in Jiangsu Province (Zhangjiagang and Yancheng), Anhui Province (Xuancheng), Thailand (Ayutthaya), and Morocco, with products exported to over 50 countries and regions including Europe, America, Japan, South Korea, the Middle East, and Africa [2] - Zhonglun Law Firm serves as the issuer's lawyer for Aishalon's public offering and listing project on the Beijing Stock Exchange, providing comprehensive and high-quality legal services throughout the issuance and listing process [2] - The project team includes partners Sun Yu and Qiao Wenjun, along with lawyer Wu Weiwei, and regional partner Cheng Chi, demonstrating a rigorous and professional service approach [2]

Group 1 - Aishalon Medical Technology Group Co., Ltd. has been listed on the Beijing Stock Exchange, marking it as the first new A-share listed company in Jiangsu Province for 2026 and the first in Suzhou's Xiangcheng District [1] - The company's stock price surged by 175.59% on its first trading day [1] - Aishalon specializes in the research, production, and sales of disposable medical consumables, focusing on rehabilitation care and surgical infection control [1] Group 2 - The company reported a revenue of 692 million yuan and a net profit of 80.71 million yuan for 2024, with projected revenue for 2025 expected to reach between 890 million and 940 million yuan, representing a year-on-year growth of 28.65% to 35.89% [1] - Aishalon holds 46 utility model patents, 10 design patents, 21 invention patents, and 2 copyrights, with 6 invention patents currently under review [1] - The company plans to use the funds raised from its public offering of 16.92 million shares at a price of 15.98 yuan per share to invest in the "Kaipule Public Health Medical Supplies Industrial Park Construction Project," which has a total investment of 670 million yuan [2]

Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. successfully went public on January 21, becoming the first new A-share listed company in Jiangsu Province in 2026, raising a total of 270 million yuan through its IPO to fund the construction of a public health medical supplies industrial park [2] Group 1: Company Overview - Aishalon was established in 2015 and focuses on the research, production, and sales of disposable medical consumables used in rehabilitation care and medical protection [2] - The company provides products through ODM/OEM methods for internationally recognized medical device brands, expanding its product line into disinfection, home protection, and emergency protection [2] Group 2: Financial Performance - Aishalon's main business revenue for the years 2022 to the first half of 2025 was 572 million yuan, 572 million yuan, 689 million yuan, and 436 million yuan, with a compound annual growth rate of 9.73% [3] - The majority of the company's revenue comes from overseas sales, which accounted for 90.99%, 94.25%, 94.71%, and 96.54% of total revenue in the respective periods [3] - For 2025, Aishalon expects revenue to be between 890 million yuan and 940 million yuan, representing a year-on-year growth of approximately 28.65% to 35.89% [3] Group 3: Future Outlook - The successful IPO and subsequent implementation of fundraising projects will enhance Aishalon's production capacity and increase investment in the research and development of new medical consumables [4] - The company aims to actively expand its sterilization business and continuously optimize product quality and service levels [4]

随着国亮新材上市在即，截至1月22日，北交所月内上市的新股将达到3只。 对比此前情况，北交所的新股发行是否出现提速迹象？ 北交所的上市审核、新股发行正在密集开展，一周之内就有3场上市委会议、2只新股上市，以及2只新 股申购。 1月21日，爱舍伦（920050.BJ）登录北交所，上市首日大涨175.59%，当日报收44.04元/股，换手率达到 78.23%。当天，美德乐（920119.BJ）开启申购，每股发行价为41.88元，市盈率为14.99倍。明日（1月 22日），国亮新材（920076.BJ）将登陆北交所。 审核端，据北交所官网，本周（1月19日至23日），该所将共计召开3场上市委审议会议，至此，北交所 月内将安排了8场上市委会议，并连续出现"一周三审"的情况。 如何看待近期北交所的发行审核节奏？北京南山投资创始人周运南告诉第一财经，北交所新股冻资规模 持续保持高位，并有望继续冲高，市场释放出赚钱效应，市场高度期待北交所的新股上市提速、高质量 扩容。另有分析认为，结合2025年上市审核情况，北交所IPO正呈现"加速跑"态势。 一周三审、2股上市、2股打新 本周上市的2只新股爱舍伦、国亮新材，IPO申请均在 ...

Group 1 - The core point of the news is the issuance of new stocks in the market, with a total of 8 companies raising a cumulative amount of 7.498 billion yuan so far this year, averaging 937 million yuan per company [1][2] - The newly issued stocks include 2 from the Shanghai main board, 1 from the Sci-Tech Innovation Board, and 5 from the Beijing Stock Exchange, with total fundraising amounts of 4.158 billion yuan, 1.561 billion yuan, and 1.779 billion yuan respectively [1] - The company with the highest fundraising amount is Zhenstone Co., Ltd., raising 2.919 billion yuan primarily for the construction of fiberglass product production bases and composite material production bases [1] Group 2 - The average initial issuance price of new stocks this year is 28.82 yuan, with the highest price being 92.18 yuan for Hengyun Chang, followed by Meidele and Nongda Technology at 41.88 yuan and 25.00 yuan respectively [2] - The geographical distribution of newly issued stocks shows a concentration in Zhejiang, Liaoning, and Jiangsu, with the highest fundraising amounts from Zhejiang, Guangdong, and Chongqing at 3.163 billion yuan, 1.561 billion yuan, and 1.240 billion yuan respectively [2] - The detailed list of newly issued stocks includes Zhenstone Co., Ltd. with 26,105.50 million shares at 11.18 yuan raising 2.919 billion yuan, and Hengyun Chang with 1,693.06 million shares at 92.18 yuan raising 1.561 billion yuan [2]

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. (stock code: 920050.BJ) was listed on the Beijing Stock Exchange, opening at 48.88 yuan and closing at 44.04 yuan, with a significant increase of 175.59% and a total market capitalization of 2.981 billion yuan [1]. Company Overview - Aishalon focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables for rehabilitation care and medical protection [1]. - The company provides products to internationally renowned medical device brands through ODM/OEM methods [1]. Shareholding Structure - The controlling shareholder is Jiangsu Novick Technology Investment Co., Ltd., with Zhang Yong as the actual controller, holding a total of 88.69% of the company's shares [1][2]. - After the issuance, Zhang Yong directly holds 1,000,000 shares (1.48%) and indirectly controls 45,017,025 shares (66.52%) [2]. Financial Performance - In 2022, 2023, and 2024, Aishalon's revenue was 573.56 million yuan, 574.66 million yuan, and 691.64 million yuan, respectively, with net profits of 62.80 million yuan, 66.94 million yuan, and 80.61 million yuan [7]. - For the first half of 2025, the revenue was 438.20 million yuan, with a net profit of 49.43 million yuan [8]. - The company reported a revenue of 68.96 million yuan for the first nine months of 2025, a year-on-year increase of 42.84%, and a net profit of 7.31 million yuan, up 26.98% [11]. Fundraising and Investment Projects - Aishalon raised a total of 270.38 million yuan, with a net amount of 240.18 million yuan allocated for the construction of the Caprol Public Health Medical Supplies Industrial Park [5]. - The total investment for the Caprol project is 670.46 million yuan, with 300 million yuan funded through this issuance [6]. Future Projections - The company expects 2025 revenue to be between 889.82 million yuan and 939.87 million yuan, representing a growth of 28.65% to 35.89% compared to 2024 [12]. - The projected net profit for 2025 is estimated to be between 89.29 million yuan and 98.48 million yuan, indicating a growth of 10.63% to 22.01% [12].

Core Viewpoint - Jiangsu Aisheren Medical Technology Group Co., Ltd. successfully went public on the Beijing Stock Exchange, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District on the North Exchange [1][6]. Company Overview - Aisheren focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables used in rehabilitation care and medical protection [3][8]. - The company provides products through ODM/OEM methods for internationally renowned medical device brands, continuously expanding its product line to include disinfection, home protection, and emergency protection [3][9]. - Aisheren has obtained several certifications, including ISO13485:2016, EU CE certification, and US FDA registration, meeting high global standards for medical consumables [3][9]. Future Plans - The successful IPO will serve as a catalyst for Aisheren to enhance existing production capacity and increase investment in the research and development of new medical consumables [3][9]. - The company aims to actively expand its sterilization business and continuously optimize product quality and service levels [3][9]. - Aisheren plans to leverage the Belt and Road Initiative to deepen its presence in the global medical dressing market, contributing more Chinese wisdom and strength to global healthcare [3][9]. Role of Dongwu Securities - Dongwu Securities acted as the sponsor and underwriter for Aisheren's IPO, showcasing its expertise in the medical consumables sector and enhancing its brand influence in the North Exchange [5][11]. - The firm has successfully sponsored and underwritten 48 companies in Suzhou, with a nearly 50% market share of Suzhou companies listed on the North Exchange [5][11]. - Dongwu Securities aims to continue its commitment to high-quality development and to advance towards becoming a leading investment bank characterized by specialization, market orientation, technological advancement, and internationalization [5][11].